Idiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases and is characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first disease-modifying therapy (DMT) approved for IPF, followed soon after by Boehringer Ingelheim’s nintedanib (Ofev); these therapies set the stage for fierce competition in the IPF therapy market. We explore this evolving space, analyzing the clinical and commercial outlook for pirfenidone and nintedanib. We assess emerging therapies, including FibroGen’s IV-administered pamrevlumab, Roche’s IV-administered PRM-151, and United Therapeutics’ inhaled treprostinil. We also examine current medical practice and identify the areas of pressing unmet need in the treatment of the disease.
QUESTIONS ANSWERED
How will the size of the IPF population change through 2030? How large are the key subpopulations? What percentage of the IPF population receives drug treatment?
How do interviewed experts view the clinical profiles of Esbriet and Ofev, and what factors drive or constrain their use? What are the most pressing unmet clinical needs in the management of IPF, according to experts?
Which emerging therapies do IPF experts consider most promising? If approved, how would emerging therapies influence the management of IPF and the market position of Ofev and Esbriet? What is the commercial potential of pamrevlumab, PRM-151, and treprostinil?
PRODUCT DESCRIPTION
Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.